INTRODUCTION: Patient compliance with osteoporosis drug therapy is often poor in clinical practice and may be associated with higher risk of fracture. METHODS: A nested case-control study was undertaken using a US health insurance claims database. The source population included all women aged >or=45 years who began drug therapy for osteoporosis. Cases consisted of those who experienced an osteoporosis-related fracture; they were matched to controls without osteoporosis-related fracture. Compliance with osteoporosis drug treatment was assessed in terms of the number of therapy-days received and medication possession ratio (MPR). Conditional logistic regression was employed to examine the relationship between compliance and fracture risk. RESULTS: A total of 453 women with osteoporosis-related fracture were identified and matched to 2,160 controls. Fracture risk was significantly lower for patients with >180 days of therapy [181-360 days: odds ratio (OR) = 0.70, 95% CI = 0.49-0.99; >360 days: OR = 0.65, 95% CI = 0.43-0.99) versus those with <or=30 days. Risk was also lower for patients with MPR >or=90% (OR = 0.70, 95% CI = 0.52-0.93) versus those with MPR <30%. Fracture risk decreased as compliance increased (p(trend) < 0.05). CONCLUSION: Among women initiating drug therapy for osteoporosis, better compliance is associated with reduced risk of fracture.
INTRODUCTION:Patient compliance with osteoporosis drug therapy is often poor in clinical practice and may be associated with higher risk of fracture. METHODS: A nested case-control study was undertaken using a US health insurance claims database. The source population included all women aged >or=45 years who began drug therapy for osteoporosis. Cases consisted of those who experienced an osteoporosis-related fracture; they were matched to controls without osteoporosis-related fracture. Compliance with osteoporosis drug treatment was assessed in terms of the number of therapy-days received and medication possession ratio (MPR). Conditional logistic regression was employed to examine the relationship between compliance and fracture risk. RESULTS: A total of 453 women with osteoporosis-related fracture were identified and matched to 2,160 controls. Fracture risk was significantly lower for patients with >180 days of therapy [181-360 days: odds ratio (OR) = 0.70, 95% CI = 0.49-0.99; >360 days: OR = 0.65, 95% CI = 0.43-0.99) versus those with <or=30 days. Risk was also lower for patients with MPR >or=90% (OR = 0.70, 95% CI = 0.52-0.93) versus those with MPR <30%. Fracture risk decreased as compliance increased (p(trend) < 0.05). CONCLUSION: Among women initiating drug therapy for osteoporosis, better compliance is associated with reduced risk of fracture.
Authors: Maria-Teresa Cuddihy; Sherine E Gabriel; Cynthia S Crowson; Elizabeth J Atkinson; Claudia Tabini; W Michael O'Fallon; L Joseph Melton Journal: Arch Intern Med Date: 2002-02-25
Authors: B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings Journal: JAMA Date: 1999-08-18 Impact factor: 56.272
Authors: U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus Journal: N Engl J Med Date: 1995-11-30 Impact factor: 91.245
Authors: Adrianne C Feldstein; Gregory A Nichols; Patricia J Elmer; David H Smith; Mikel Aickin; Michael Herson Journal: J Bone Joint Surg Am Date: 2003-12 Impact factor: 5.284
Authors: D Weycker; L Lamerato; S Schooley; D Macarios; T Siu Woodworth; N Yurgin; G Oster Journal: Osteoporos Int Date: 2012-08-18 Impact factor: 4.507